The Motley Fool

Here’s the secret behind CSL’s monster 42% return on equity

Last week I noted that blood product company CSL Limited (ASX: CSL) was building up a steady history of monster returns on equity (roe).

At 42% these returns are far above the 6% industry average hinting at a company with a strong, sustainable competitive advantage. But where is the high return coming from?

Breaking down return on equity

To see where CSL’s huge 42% ROE comes from, we can break it out into three components using a method called DuPont analysis:

  • Net profit margin (Net Income ÷ Revenue) 0.22
  • Asset Turnover (Revenue ÷ Assets) 0.73
  • Equity Multiplier (Assets ÷ Shareholders’ Equity) 2.64
  • Return on equity = (0.22) x (0.73) x (2.64) = 42%

Even by healthcare standards CSL’s 42% ROE is impressive, with Cochlear Limited (ASX: COH) being one of the few companies to come close at 40%.

But when we break it down we can see that the big driver of the returns is in fact CSL’s use of debt to fund assets; the high equity multiplier. Without this, if CSL didn’t leverage its assets with borrowed money, ROE would only be 16%.

Why does CSL use debt, rather than fund growth from its strong cash flows? With borrowing costs so low it makes sense to use debt to fund moderate growth if the company knows it can generate new income above it’s average cost of capital to pay it back.

CSL has strong cash flows to service its interest payments, but if a comparable investment had a higher unleveraged return, we may prefer to buy it.

Foolish takeaway

To me, CSL is to healthcare what Johnson & Johnson is to consumer products, or what Nestlé is to snack foods; a well-structured staple producer with low cyclical volatility and strong margins and volumes.

It’s a company I would still love to own, and I will certainly be watching for any weakness in share price.

JUST RELEASED: Our Top 3 Dividend Bets for 2019

NEW! The Motley Fool’s team of crack analysts has just released a timely report revealing the names and codes of their top 3 dividend share recommendations for 2019. Be among the first investors to get access—FREE, for a strictly limited time. You’ll discover the names of 3 hefty dividend paying companies with what our analysts consider to be solid growth prospects for the year ahead…

The first two currently offer fat, fully franked yields and the third is a surprising REIT offering you the chance to become a landlord with none of the hassle! If you’re looking for hot new ideas, look no further. But you do need to hurry. Snap up your free copy now, before supplies run out!

Simply click here to grab your FREE copy of this up-to-the-minute research report on our top 3 dividend share recommendations right away.

Motley Fool contributor Regan Pearson has no position in any of the stocks mentioned.

You can follow him on Twitter @Regan_Invests.

The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

NEW. Five Cheap and Good Stocks to Buy in 2019…

Our Motley Fool experts have just released a brand new FREE report, detailing 5 dirt cheap shares that you can buy today.

One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…

Another is a diversified conglomerate trading near a 52-week low all while offering a 2.8% fully franked yield…

Plus 3 more cheap bets that could position you to profit over the next 12 months!

See for yourself now. Simply click the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.